JP2018519318A - (s)−[3,4−ジフルオロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル」)アゼチジン−1−イル]−メタノンの結晶性フマル酸塩 - Google Patents
(s)−[3,4−ジフルオロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル」)アゼチジン−1−イル]−メタノンの結晶性フマル酸塩 Download PDFInfo
- Publication number
- JP2018519318A JP2018519318A JP2017568050A JP2017568050A JP2018519318A JP 2018519318 A JP2018519318 A JP 2018519318A JP 2017568050 A JP2017568050 A JP 2017568050A JP 2017568050 A JP2017568050 A JP 2017568050A JP 2018519318 A JP2018519318 A JP 2018519318A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- hydroxy
- phenyl
- crystalline
- crystalline fumarate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 title claims abstract description 177
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title claims abstract description 58
- -1 2-fluoro-4-iodophenylamino Chemical group 0.000 title claims abstract description 57
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title claims abstract description 53
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 title claims abstract description 35
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 51
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 26
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 24
- 201000011510 cancer Diseases 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims description 157
- 239000000203 mixture Substances 0.000 claims description 86
- 239000002904 solvent Substances 0.000 claims description 46
- 239000013078 crystal Substances 0.000 claims description 38
- 239000007787 solid Substances 0.000 claims description 37
- 238000005481 NMR spectroscopy Methods 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 27
- 239000001530 fumaric acid Substances 0.000 claims description 25
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 20
- 201000001441 melanoma Diseases 0.000 claims description 20
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- 238000001228 spectrum Methods 0.000 claims description 16
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 15
- 229960003862 vemurafenib Drugs 0.000 claims description 13
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 12
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 12
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 238000005259 measurement Methods 0.000 claims description 11
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 9
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 7
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 3
- 238000001757 thermogravimetry curve Methods 0.000 claims description 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 45
- 239000003826 tablet Substances 0.000 description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 26
- 235000002639 sodium chloride Nutrition 0.000 description 25
- 229960002598 fumaric acid Drugs 0.000 description 24
- 229940050411 fumarate Drugs 0.000 description 23
- 239000000725 suspension Substances 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 238000002425 crystallisation Methods 0.000 description 15
- 230000008025 crystallization Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 238000007906 compression Methods 0.000 description 14
- 230000006835 compression Effects 0.000 description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 13
- 239000013543 active substance Substances 0.000 description 12
- SVTPHAFLJUCRLW-UHFFFAOYSA-N azetidine-1-carbaldehyde Chemical compound O=CN1CCC1 SVTPHAFLJUCRLW-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000008187 granular material Substances 0.000 description 11
- 238000003801 milling Methods 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000007884 disintegrant Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000000945 filler Substances 0.000 description 9
- 239000000314 lubricant Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 229920002785 Croscarmellose sodium Polymers 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000002441 X-ray diffraction Methods 0.000 description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 229960001681 croscarmellose sodium Drugs 0.000 description 8
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000011877 solvent mixture Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 238000002336 sorption--desorption measurement Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 101710113436 GTPase KRas Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229960002271 cobimetinib Drugs 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000007888 film coating Substances 0.000 description 4
- 238000009501 film coating Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108010014186 ras Proteins Proteins 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001360 collision-induced dissociation Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 229960001433 erlotinib Drugs 0.000 description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 238000010996 solid-state NMR spectroscopy Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229940033134 talc Drugs 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
- WEPXLRANFJEOFZ-UHFFFAOYSA-N 2,3,4-trifluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(F)=C1F WEPXLRANFJEOFZ-UHFFFAOYSA-N 0.000 description 2
- CUMTUBVTKOYYOU-UHFFFAOYSA-N 2-fluoro-4-iodoaniline Chemical compound NC1=CC=C(I)C=C1F CUMTUBVTKOYYOU-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- DRBOJCULJIZLGA-MSOLQXFVSA-N C(C)(C)(C)OC(=O)N1CC(C1)([C@H]1N(CCCC1)[C@H](CO)C1=CC=CC=C1)O Chemical compound C(C)(C)(C)OC(=O)N1CC(C1)([C@H]1N(CCCC1)[C@H](CO)C1=CC=CC=C1)O DRBOJCULJIZLGA-MSOLQXFVSA-N 0.000 description 2
- XFURMJOWXGLMGN-LVCYWYKZSA-N CC(C)(C)OC(=O)N1CC(O)(C1)[C@@]1(CCC[C@@H]2OC[C@@H](N12)c1ccccc1)C#N Chemical compound CC(C)(C)OC(=O)N1CC(O)(C1)[C@@]1(CCC[C@@H]2OC[C@@H](N12)c1ccccc1)C#N XFURMJOWXGLMGN-LVCYWYKZSA-N 0.000 description 2
- KZFAHANGHMLHTB-AMTWEWDESA-N Cl.Cl.OC[C@@H](N1CCCC[C@H]1C1(O)CNC1)c1ccccc1 Chemical compound Cl.Cl.OC[C@@H](N1CCCC[C@H]1C1(O)CNC1)c1ccccc1 KZFAHANGHMLHTB-AMTWEWDESA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 229910000760 Hardened steel Inorganic materials 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- KAXYRJIPEGDXGR-MOPGFXCFSA-N [3-hydroxy-3-[(2s)-1-[(1s)-2-hydroxy-1-phenylethyl]piperidin-2-yl]azetidin-1-yl]-(2,3,4-trifluorophenyl)methanone Chemical compound C1C([C@@H]2CCCCN2[C@H](CO)C=2C=CC=CC=2)(O)CN1C(=O)C1=CC=C(F)C(F)=C1F KAXYRJIPEGDXGR-MOPGFXCFSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 239000012296 anti-solvent Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000012455 biphasic mixture Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 2
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000009490 roller compaction Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 229940034727 zelboraf Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000004922 13C solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- NXRQXCFBZGIRGN-UHFFFAOYSA-N 2,3,4-trifluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C(F)=C1F NXRQXCFBZGIRGN-UHFFFAOYSA-N 0.000 description 1
- SWNIFANHJGMBIM-UHFFFAOYSA-N 2,3-dihydroxypropyl hexadecanoate;octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(=O)OCC(O)CO SWNIFANHJGMBIM-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229940125431 BRAF inhibitor Drugs 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- 230000005723 MEK inhibition Effects 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- IUKQLMGVFMDQDP-UHFFFAOYSA-N azane;piperidine Chemical compound N.C1CCNCC1 IUKQLMGVFMDQDP-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000006510 metastatic growth Effects 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical group O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940023144 sodium glycolate Drugs 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000004441 surface measurement Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000005469 synchrotron radiation Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960003487 xylose Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Description
本出願は、2015年6月30日に出願された米国仮特許出願第62/187,009号に対する優先権を主張する。上述の出願の全内容が本明細書に組み込まれる。
。
化合物I
WO2007/044515は、(S)−[3,4−ジフルオロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル」)アゼチジン−1−イル]−メタノンの合成を記載し、かつこの分子のMEKを阻害、制御、及び/または調節する治療活性を開示する(Biochemical Assay、268ページ)。化合物Iは、米国、ヨーロッパ、及び他のメラノーマを治療する場所でベムラフェニブ(ゼルボラフ(登録商標))との組み合わせで認可されている。
。
本開示は、化合物Iの結晶性フマル酸塩に関する。また本開示は、化合物Iの結晶性フマル酸塩の医薬品組成物に関する。フマル酸塩は、(S)−[3,4−ジフルオロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル」)アゼチジン−1−イル−メタノン(化合物I)とフマル酸を化合させることにより製造されてよく、2:1の化合物I:フマル酸の化学量論を有する塩を形成する。化合物Iの結晶性フマル酸塩はヘミフマル酸塩を指してもよい。
。
(i)実質的に図2に示されるような、DMSO−d6中の1H NMRスペクトル、
(ii)実質的に図3に示されるような、DMSO−d6中の13C NMRスペクトル、
(iii)175.3、173.6、117.5、155.5、及び153.5、±0.2ppmから選択される3以上のピークを有する、13C NMR固体スペクトル、
(iv)実質的に図4に示されるような、13C NMR固体スペクトル、
(v)4.6、12.1、13.2、13.6及び14.5±0.2°2θから選択される3以上の2θ値を有する粉末X線回析パターン(CuKα λ=1.5418Å)(結晶性形態の測定は室温で行われる)、
(vi)図10に示されるパターンに実質的に従うX線粉末回折(XRPD)パターン、ならびに
(vii)図8に実質的に従う示差走査熱量測定サーモグラム。
結晶系:正方晶
空間群:P43212
晶癖:薄板状
単位格子サイズ
a=7.8825Å
b=7.8825Å
c=76.846Å
α=90°
β=90°
γ=90°
温度:293K
格子体積:4774.7Å3
格子単位中の分子:8
密度:1.637g/cm3
形態Aの単位格子パラメータは約25℃、例えば、外気温または室温において計測した。
本開示の他の態様は、化合物Iの結晶性フマル酸塩、及び医薬的に許容される1以上の賦形剤を含む医薬品組成物に関する。化合物Iの結晶性フマル酸塩の量は、治療的に有効量であってよい。本開示の他の態様は、化合物Iの結晶性フマル酸塩、またはそれらの組み合わせ、及び医薬的に許容される賦形剤を含む固体もしくは分散液医薬品組成物に関する。
表A
表B
表C
表D
表E
表F
本開示の他の態様は、癌の治療方法であって、それを必要とする患者に化合物Iの結晶性フマル酸塩を投与することを含む、方法に関する。特定の実施形態においては、化合物Iの結晶性フマル酸塩は形態Aである。投与される化合物Iの結晶性フマル酸塩の量は、治療的に許容される有効量であってよい。
化合物Iは、WO2014/059422に記載のように調製することができ、これは全内容が参照により本明細書に組み入れられ、かつ一般的にはスキーム1に示される。塩基の存在下で、市販で入手可能な(3S,5R,8aS)−3−フェニル−ヘキサヒドロ−オキサゾロ[3,2−a]ピリジン−カルボニトリルVIIと市販で入手可能なtert−ブチル「−3−オキソ−1−アデチジンカルボキシレートVIIaとの反応により化合物VIが調製される。化合物VIを、酸の存在下で、シアノ水素化ホウ素ナトリウムなどの水素化物還元剤と処理し、続いて水性水酸化ナトリウムと処理して化合物Vを得る。酸を用いたVの脱保護により化合物IVを得られ、これを、触媒量のピリジンの存在下で、酸塩化物IVaと結合してIIIを得る。IIIの水素化によりピペリジン誘導体IIを得る。最後に、IIと2−フルオロ−4−ヨードアニリンIIaのカップリングにより、所望の化合物を得る。
スキーム1
結晶性形態の一般的な製造方法
溶媒中に溶解したフマル酸を溶媒に溶解した化合物Iの混合物に添加し、形態Aと称される化合物Iの結晶性フマル酸塩を形成すること;及び
得られた形態Aと称される化合物Iの結晶性フマル酸塩の結晶を採取すること。
第1の溶媒に化合物Iを溶解させて第1の混合物を形成すること;
第2の溶媒にフマル酸を溶解させて第2の混合物を形成すること;
第1の混合物を第2の混合物に冷却しながら添加し、沈殿物として結晶を形成すること;及び
形態Aと称される化合物Iの結晶性フマル酸塩の結晶を採取すること。
溶媒中に溶解したフマル酸を溶媒中に溶解した化合物Iの混合物を添加し、形態Aと称される化合物Iの結晶性フマル酸塩を形成すること。
本発明は、以下の非限定実施形態によって特徴づけられる。
(i)実質的に図2に示されるような、d6DMSO中の1H NMRスペクトル、
(ii)実質的に図3に示されるような、d6DMSO中の13C NMRスペクトル、
(iii)175.3、173.6、117.5、155.5、及び153.5、±0.2ppmから選択される3以上のピークを有する、13C NMR固体スプペクトル、
(iv)実質的に図4に示されるような、13C NMR固体スプペクトル、
(v)結晶性形態の測定は室温で行われる、4.6、12.1、13.2、13.6及び14.5±0.2°2θから選択される3以上の2θ値を有する粉末X線回析パターン(CuKα λ=1.5418Å)、
(vi)実質的に図10に示されるパターンに従う、粉末X線回析(XRPD)パターン、ならびに
(vii)実質的に図8に従う、示差走査熱量測定サーモグラム。
3−((3S,5R,8aS)−5−シアノ−3−フェニル−ヘキサヒドロ−オキサゾロ[3,2−a]ピリジン−5−イル)−3−ヒドロキシ−アゼチジン−1−カルボン酸tert−ブチルエステルの合成
HPLC純度:91.9%−面積 Mp.(DSC:外挿ピーク:151.80℃.1H−NMR(600MHz,CDCl3):7.30〜7.50(m,5 H),4.17 − 4.27(m,3 H),3.94〜4.01(m,2 H),4.11−4.1(m,2 H),4.09(d,1 H),3.95(d,1H),3.87(dd,1H),3.76(dd,1H),3.54〜3.70(br,1H),2.85〜3.03(br,1H),2.18〜2.25(m,1H),2.12(br,1H),1.97〜2.04(m,1H),1.85〜1.94(m,1H),1.61〜1.79(m,3H),1.41(s,9H).MS(EI):m/z=400.48([M+H]+,100%)
3−ヒドロキシ−3−[(S)−1−((S)−2−ヒドロキシ−1−フェニル−エチル)−ピペリジン−2−yl]アゼチジン−1−カルボン酸tert−ブチルエステルの合成
3−[(S)−1−((S)−2−ヒドロキシ−1−フェニル−エチル)−ピペリジン−2−イル]−アゼチジン−3−オールジヒドロクロリドの合成
{3−ヒドロキシ−3−[(S)−1−((S)−2−ヒドロキシ−1−フェニル−エチル)−ピペリジン−2−イル]−アゼチジン−1−イル}−(2,3,4−トリフルオロ−フェニル)−メタノン
2,3,4−トリフルオロ安息香酸(100g、568mmol、1.0当量)を、トルエン(1000mL)中で懸濁し、ピリジン(0.254mL、3.15mmol、0.0055当量)で処理した。得られた懸濁液を60〜70℃に加熱すると、混合物は透明な黄みがかった溶液となった。この温度で、塩化オキサリル(94.4g、729mmol、1.3当量)を、156分にわたってゆっくりと添加した。添加が完了した後、完全になるまで10分間撹拌し続けた。真空下(ジャケット温度:60〜70℃、圧力:200〜100mbar)での蒸留により、トルエン(360mL)を部分的に除去した。水溶液を室温まで冷却し、黄みがかりわずかに濁った溶液636gを得、それをN2雰囲気中で保存し、その後のステップでさらに処理するにことなく使用した。HPLC純度:99.2%−面積
3−[(S)−1−((S)−2−ヒドロキシ−1−フェニル−エチル)−ピペリジン−2−イル]−アゼチジン−3−オールジヒドロクロライド水溶液(43.5g)をEtOH(24mL)で処理し10分間室温で撹拌した。この混合物に、261mLの水中のリン酸三カリウムの溶液(28.8g、136mmol、4.7当量)を14分以内に10〜20℃のバッチ温度で加え、混合物を15℃で15分間撹拌した(pH11.9)。この水溶液に、滴下漏斗によって34gの上記の2,3,4−トリフルオロ安息香酸(34.0g、29.8mmol、1.0当量)を、激しく撹拌しながら、32分にわたって10〜20℃のバッチ温度で加えた。滴下漏斗をトルエン(1.2mL)ですすぎ、二相性混合物を室温で60分間撹拌した。相を分離させ、水相を廃棄した。有機相を水(42g)中の炭酸ナトリウム(3.36g、31.5mmol、1.09当量)で洗浄し、室温で30分撹拌した。層を分離させ、有機相を塩化ナトリウム水溶液(30g、10%w/w)で洗浄した。ロータリーエバポレーター(浴温50℃、圧力200mbar未満)において、有機相を体積約30%まで濃縮した。残渣をEtOH(23mL)に取り入れ、40〜50℃で5分間撹拌した。再度、溶液をロータリーエバポレーター(浴温50℃、圧力200mbar未満、17ml蒸留物)で濃縮し、非常に粘稠性の油状物を得た。残渣を再度EtOH(23mL)に取り入れ、10分間撹拌し、目的の容量(53mL、46.06g)に達するために再度さらにEtOH(12mL)で希釈した。HPLC純度:85.0%−面積
((S)−3−ヒドロキシ−3−ピペリジン−2−イル−アゼチジン−1−イル)−(2,3,4−トリフルオロ−フェニル)−メタノンヒドロクロリドの合成
(S)−[3,4−ジフルオロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル」)アゼチジン−1−イル]−メタノン(化合物I)の合成
形態Aと称される(S)−[3,4−ジフルオロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル」)アゼチジン−1−イル]−メタノン(化合物I)の結晶性フマル酸塩の調整
元素分析結果を1178.71g/molの相対分子量及び C46H46F6I2N6O8の組成からから算出し、表1に示す。結果は上記の構造と一致している。
表1:C46H46F6I2N6O8の元素分析
iD5 ATRアクセサリを備えたThermoScientificのiS5フーリエ変換赤外(FTIR)分光光度計を使用した。赤外線(IR)スペクトルは、4000〜650cm−1の範囲内で反射IR測定値として記録され、図1に示されている。IRスペクトルは上記の構造と一致している。特徴的なIR伸縮の概要を表2に示す。
表2:化合物Iのフマル酸塩のIR割り当て
核磁気共鳴(NMR)測定を、Bruker Avance600及び400MHz分光計で行った。600MHzの機械には5mmのTCI、z−gradient CryoProbeが装備され、400MHzの機械には5mmのBBFO、z−gradient Probeが装備されていた。試料は、全ての陽子検出実験のために、DMSO−d6(D、99.8%)0.75mL中の形態Aと称される化合物Iの結晶性フマル酸塩6mgを溶解することによって調製した。13C−NMR及び19F−NMRのためには、0.75mLのDMSO−d6に62mgを溶解させた。
アジレント6520QTOF分光計を、ESI正CID MSMS及びESI負MSに使用した。化合物Iのフマル酸塩について得られた陽イオンエレクトロスプレー質量スペクトルを図5に示す。562.0714m/zの[M+H]+は化合物I(遊離塩基)の化学式と一致している。M+Hの断片化挙動は、衝突誘起解離(CID)によって試験された。窒素を衝突ガスとして使用した。すべてのフラグメントは、化合物Iの構造と良好な相関関係にあった。
粉末X線回析(XRPD)試験
単結晶をループに乗せ、大気温度で測定した。データは、シンクロトロン放射を伴うDECTRIS Pilatus 6M検出器及びプログラムXDSで処理されたデータを備えたSwiss Light SourceビームラインX10SAで収集した。結晶構造を解析し、ShelXTL(Bruker AXS,Karlsruhe)で精緻化した。
表3: 形態A結晶データ
形態Aの子立体構造及び結晶構造パラメータを表3に示す。形態Aの結晶構造では、ピペリジン窒素はプロトン化され、フマル酸は脱プロトン化される。フマル酸塩は、2つのピペリジン及び異なる活性の分子からの2つのOH基によって配位される。結晶充填は無限の分子間水素結合鎖により特徴づけられる。絶対構造パラメータ(Flackパラメータ:0.048、esd 0.013)によって示されるように、ピペリジン環のキラル炭素原子の立体配置が(S)であることが確認された。
約200nm、239nm、276nm及び310nmのUV−Vis吸収極大は、それぞれ芳香族環部分ならびにn→π*孤立電子対のπ→π*遷移を示す。図7におけるスペクトルは、化合物Iのフマル酸塩の構造と一致し、かつ構造内に存在する発色団の期待される特徴を示す。
15を超える化合物Iの塩形態を、例えば、安息香酸、マロン酸、フマル酸、マンデル酸、酢酸及びオロチン酸から調製された塩を含む臨床開発のための適合性について評価した。安息香酸、マロン酸、マンデル酸、酢酸及びオロチン酸が、溶媒及び条件に応じて非晶質塩、結晶塩、または非晶質塩と結晶塩の混合物を形成する場合、以下に説明するようにフマル酸から調製された塩が最も望ましいことが明らかとなった。
Mettler−Toledo社製機器(DSC820/821e/1;FRS05センサー)を用いてDSCサーモグラムを記録した。試料約2〜6mgをアルミニウム蒸発皿に入れ、アルミニウム蓋で密封した。加熱前に蓋を自動的に穿孔した。通常、窒素下の試料を10K/分の比率で最大250℃まで加熱した。
周囲条件でSTOE社製STADI P回折計(CuKα線[1.54Å]、一次モノクロメーター、シリコンストリップ検出器、角度範囲3°〜42°2−θ、総測定時間約30分)を用いて、透過幾何学におけるX線回析パターンを記録した。試料を用意し、さらなる材料の処理(例えば、粉砕またはふるい)をせずに分析した。
表4
それぞれの固有溶解測定のため、フラットディスク(表面積=0.5cm2)に約15kNの負荷をかけて、結晶性形態Aまたは非晶形試料からペレットを製造した。圧縮後、それぞれのペレットをXRPDによって点検し、ペレット成型工程中に多形性変換が起きていないことを確かめた。使用した実験条件を表5にまとめる。
表5
表6
水分吸着/脱離データをDVS−1/DVS−HT/DVS−内因性(SMS表面測定システム)水分バランスシステムで収集した。吸着/脱着等温線は、25℃で0%RH(相対湿度)から90%RHの範囲で段階的に測定した。RHの次のレベル(重量基準が満たされない場合、最大平衡時間24時間)に切り替える基準として、0.002mg/分未満の重量変化が選択された。データを試料の初期水分量に対して修正;つまり、0%RHで試料が乾燥した後の重量をゼロ点として取った。所定の物質の吸湿性は、表7に示すように、RHを0%RHから90%RHに上げたときの質量の増加を特徴とする。
表7
Claims (14)
- (S)−[3,4−ジフロロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル」)アゼチジン−1−イル]−メタノンの結晶性フマル酸塩。
- 形態Aと称され、以下のうちの少なくとも1によって特徴づけられる、請求項1に記載の結晶性フマル酸塩:
(i)実質的に図2に示されるような、d6DMSO中の1H NMRスペクトル、
(ii)実質的に図3に示されるような、d6DMSO中の13C NMRスペクトル、
(iii)175.3、173.6、117.5、155.5、及び153.5、±0.2ppmから選択される3以上のピークを有する、13C NMR固体スプペクトル、
(iv)実質的に図4に示されるような、13C NMR固体スプペクトル、
(v)4.6、12.1、13.2、13.6及び14.5±0.2°2θから選択される3以上の2θ値を有する粉末X線回析パターン(CuKα λ=1.5418Å)(結晶性形態の測定は室温で行われる)、
(vi)実質的に図10に示されるパターンに従う、粉末X線回析(XRPD)パターン、ならびに、
(vii)実質的に図8に従う、示差走査熱量測定サーモグラム。 - 前記塩は、175.3、173.6、117.5、155.5、及び153.5、±0.2ppmから選択される3以上のピークを有する、13C NMR固体スプペクトルによって特徴づけられる、請求項1に記載の、形態Aと称される、(S)−[3,4−ジフロロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル」)アゼチジン−1−イル]−メタノンの結晶性フマル酸塩。
- 前記塩は、4.6、12.1、13.2、13.6及び14.5±0.2°2θから選択される3以上の2θ値を含む粉末X線回析パターン(CuKα λ=1.5418Å)によって特徴づけられ、結晶性形態の測定は室温で行われる、請求項1に記載の、形態Aと称される、(S)−[3,4−ジフロロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル」)アゼチジン−1−イル]−メタノンの結晶性フマル酸塩。
- 前記塩は、前記塩の重量に基づき少なくとも90重量%の形態Aである、請求項1〜4に記載の(S)−[3,4−ジフロロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル」)アゼチジン−1−イル]−メタノンの結晶性フマル酸塩。
- 請求項1〜4に記載の、形態Aと称される、(S)−[3,4−ジフロロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル」)アゼチジン−1−イル]−メタノンの結晶性フマル酸塩、及び医薬的に許容される賦形剤を含む、医薬品組成物。
- 癌を治療するための医薬品を製造するための、請求項1〜4のいずれか1項に記載の、形態Aと称される、(S)−[3,4−ジフロロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル」)アゼチジン−1−イル]−メタノンの結晶性フマル酸塩の使用。
- 癌治療における療法ための、請求項1〜4のいずれかに1項に記載の、形態Aと称される、(S)−[3,4−ジフロロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル」)アゼチジン−1−イル]−メタノンの結晶性フマル酸塩の使用。
- メラノーマ(BRAF V600変異メラノーマを含む)、乳癌(三種陰性乳癌を含む)、結腸直腸癌(KRAS変異結腸直腸癌を含む)、非小細胞肺癌、急性骨髄性白血病、及び膵癌からなる群から選択される癌を治療するための医薬品として使用する、形態Aと称される(S)−[3,4−ジフロロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル」)アゼチジン−1−イル]−メタノンの結晶性フマル酸塩。
- 前記癌は、BRAF V600変異メラノーマである、請求項8に記載の使用。
- ベムラフェニブと組み合わせて、メラノーマ治療のための医薬品として使用される、形態Aと称される(S)−[3,4−ジフルオロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル」)アゼチジン−1−イル]−メタノンの結晶性フマル酸塩。
- 対象におけるBRAF V600変異メラノーマの治療方法であって、化合物Iの結晶性フマル酸塩の治療有効量を、単独でまたはベムラフェニブと組み合わせて治療を必要とする前記対象に投与することを含む、前記方法。
- 前記化合物Iの結晶性フマル酸塩がベムラフェニブの前または後、もしくは同時に投与される、請求項12に記載の方法。
- 溶媒中に溶解したフマル酸を溶媒に溶解した化合物Iの混合物に添加し、形態Aと称される化合物Iの結晶性フマル酸塩を形成すること、及び得られた形態Aと称される化合物Iの結晶性フマル酸塩の結晶を採取すること
を含む、形態Aと称される化合物Iの結晶性フマル酸塩を調製する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562187009P | 2015-06-30 | 2015-06-30 | |
US62/187,009 | 2015-06-30 | ||
PCT/US2016/040444 WO2017004393A1 (en) | 2015-06-30 | 2016-06-30 | Crystalline fumarate salt of (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020184868A Division JP2021035967A (ja) | 2015-06-30 | 2020-11-05 | (s)−[3,4−ジフルオロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル)アゼチジン−1−イル]−メタノンの結晶性フマル酸塩 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018519318A true JP2018519318A (ja) | 2018-07-19 |
JP7338950B2 JP7338950B2 (ja) | 2023-09-05 |
Family
ID=56411938
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017568050A Active JP7338950B2 (ja) | 2015-06-30 | 2016-06-30 | (s)-[3,4-ジフルオロ-2-(2-フルオロ-4-ヨードフェニルアミノ)フェニル][3-ヒドロキシ-3-(ピペリジン-2-イル」)アゼチジン-1-イル]-メタノンの結晶性フマル酸塩 |
JP2020184868A Withdrawn JP2021035967A (ja) | 2015-06-30 | 2020-11-05 | (s)−[3,4−ジフルオロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル)アゼチジン−1−イル]−メタノンの結晶性フマル酸塩 |
JP2022178184A Pending JP2023025000A (ja) | 2015-06-30 | 2022-11-07 | (s)-[3,4-ジフルオロ-2-(2-フルオロ-4-ヨードフェニルアミノ)フェニル][3-ヒドロキシ-3-(ピペリジン-2-イル)アゼチジン-1-イル]-メタノンの結晶性フマル酸塩 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020184868A Withdrawn JP2021035967A (ja) | 2015-06-30 | 2020-11-05 | (s)−[3,4−ジフルオロ−2−(2−フルオロ−4−ヨードフェニルアミノ)フェニル][3−ヒドロキシ−3−(ピペリジン−2−イル)アゼチジン−1−イル]−メタノンの結晶性フマル酸塩 |
JP2022178184A Pending JP2023025000A (ja) | 2015-06-30 | 2022-11-07 | (s)-[3,4-ジフルオロ-2-(2-フルオロ-4-ヨードフェニルアミノ)フェニル][3-ヒドロキシ-3-(ピペリジン-2-イル)アゼチジン-1-イル]-メタノンの結晶性フマル酸塩 |
Country Status (24)
Country | Link |
---|---|
US (3) | US10590102B2 (ja) |
EP (1) | EP3317264A1 (ja) |
JP (3) | JP7338950B2 (ja) |
KR (1) | KR20180021775A (ja) |
CN (1) | CN107810183A (ja) |
AR (1) | AR105483A1 (ja) |
AU (2) | AU2016288209B2 (ja) |
CA (1) | CA2990222C (ja) |
CL (1) | CL2017003475A1 (ja) |
CO (1) | CO2018000086A2 (ja) |
CR (1) | CR20180056A (ja) |
HK (1) | HK1252433A1 (ja) |
IL (2) | IL295052A (ja) |
MA (1) | MA42301A (ja) |
MX (1) | MX2017017037A (ja) |
MY (1) | MY192545A (ja) |
PE (1) | PE20180692A1 (ja) |
PH (1) | PH12017502414A1 (ja) |
RU (2) | RU2021132394A (ja) |
SG (1) | SG10202105196YA (ja) |
TW (2) | TWI710556B (ja) |
UA (1) | UA124728C2 (ja) |
WO (1) | WO2017004393A1 (ja) |
ZA (1) | ZA201708760B (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY186549A (en) | 2012-10-12 | 2021-07-26 | Exelixis Inc | Novel process for making compounds for use in the treatment of cancer |
HRP20240045T1 (hr) * | 2015-06-30 | 2024-03-29 | Genentech, Inc. | Tablete s trenutnim oslobađanjem koje sadrže lijek i postupci za proizvodnju tableta |
AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
NZ755835A (en) | 2017-01-17 | 2023-12-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
GB201717809D0 (en) * | 2017-10-30 | 2017-12-13 | Azad Pharmaceutical Ingredients Ag | Process for the production of cobimetinib |
WO2020187674A1 (en) | 2019-03-15 | 2020-09-24 | Sandoz Ag | Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010513288A (ja) * | 2006-12-14 | 2010-04-30 | エグゼリクシス, インコーポレイテッド | Mek阻害剤の使用方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101318012B1 (ko) | 2004-10-20 | 2013-10-14 | 메르크 세로노 에스.에이. | 3-아릴아미노 피리딘 유도체 |
KR101368519B1 (ko) | 2005-05-23 | 2014-02-27 | 노파르티스 아게 | 결정형 및 기타 형태의 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온 락트산염 |
EA019983B1 (ru) | 2005-10-07 | 2014-07-30 | Экселиксис, Инк. | Ингибиторы mek и способы их применения |
AU2007284562B2 (en) | 2006-08-16 | 2013-05-02 | Exelixis, Inc. | Using PI3K and MEK modulators in treatments of cancer |
WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
MY186549A (en) | 2012-10-12 | 2021-07-26 | Exelixis Inc | Novel process for making compounds for use in the treatment of cancer |
JP6835472B2 (ja) | 2013-03-05 | 2021-02-24 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 癌の処置のための組成物 |
SG11201507477XA (en) | 2013-03-14 | 2015-10-29 | Genentech Inc | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
-
2016
- 2016-06-24 AR ARP160101900A patent/AR105483A1/es unknown
- 2016-06-30 PE PE2017002869A patent/PE20180692A1/es unknown
- 2016-06-30 SG SG10202105196YA patent/SG10202105196YA/en unknown
- 2016-06-30 MY MYPI2017001962A patent/MY192545A/en unknown
- 2016-06-30 RU RU2021132394A patent/RU2021132394A/ru unknown
- 2016-06-30 TW TW105120825A patent/TWI710556B/zh active
- 2016-06-30 JP JP2017568050A patent/JP7338950B2/ja active Active
- 2016-06-30 CN CN201680039354.4A patent/CN107810183A/zh active Pending
- 2016-06-30 MA MA042301A patent/MA42301A/fr unknown
- 2016-06-30 UA UAA201800769A patent/UA124728C2/uk unknown
- 2016-06-30 CR CR20180056A patent/CR20180056A/es unknown
- 2016-06-30 KR KR1020187000067A patent/KR20180021775A/ko not_active Application Discontinuation
- 2016-06-30 RU RU2018103172A patent/RU2762181C2/ru active
- 2016-06-30 MX MX2017017037A patent/MX2017017037A/es unknown
- 2016-06-30 IL IL295052A patent/IL295052A/en unknown
- 2016-06-30 CA CA2990222A patent/CA2990222C/en active Active
- 2016-06-30 IL IL256423A patent/IL256423B/en unknown
- 2016-06-30 EP EP16738971.7A patent/EP3317264A1/en active Pending
- 2016-06-30 WO PCT/US2016/040444 patent/WO2017004393A1/en active Application Filing
- 2016-06-30 TW TW109136325A patent/TWI775187B/zh active
- 2016-06-30 AU AU2016288209A patent/AU2016288209B2/en active Active
-
2017
- 2017-12-21 ZA ZA2017/08760A patent/ZA201708760B/en unknown
- 2017-12-22 US US15/852,280 patent/US10590102B2/en active Active
- 2017-12-22 PH PH12017502414A patent/PH12017502414A1/en unknown
- 2017-12-29 CL CL2017003475A patent/CL2017003475A1/es unknown
-
2018
- 2018-01-05 CO CONC2018/0000086A patent/CO2018000086A2/es unknown
- 2018-09-12 HK HK18111734.8A patent/HK1252433A1/zh unknown
-
2020
- 2020-01-17 US US16/746,161 patent/US11254649B2/en active Active
- 2020-11-05 JP JP2020184868A patent/JP2021035967A/ja not_active Withdrawn
-
2021
- 2021-01-14 AU AU2021200202A patent/AU2021200202B2/en active Active
- 2021-11-08 US US17/521,396 patent/US20220056010A1/en not_active Abandoned
-
2022
- 2022-11-07 JP JP2022178184A patent/JP2023025000A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010513288A (ja) * | 2006-12-14 | 2010-04-30 | エグゼリクシス, インコーポレイテッド | Mek阻害剤の使用方法 |
Non-Patent Citations (6)
Title |
---|
C.G.WERMUTH編, 最新 創薬化学 下巻, vol. p.347-365, JPN6014029314, 1999, ISSN: 0004583469 * |
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 371, no. 20, JPN6020019340, 2014, pages 1867 - 1876, ISSN: 0004583467 * |
川口洋子ら: "医薬品と結晶多形", 生活工学研究, vol. 4, no. 2, JPN6014015069, 2002, pages 310 - 317, ISSN: 0004583472 * |
平山令明編著, 有機化合物結晶作製ハンドブック−原理とノウハウ−, JPN6014035600, 25 July 2008 (2008-07-25), pages 17 - 23, ISSN: 0004583470 * |
森部久仁一 等, 低温生物工学会誌, vol. 51, no. 1, JPN6020050023, 2005, pages 19 - 24, ISSN: 0004583471 * |
芦澤一英, 医薬品の多形現象と晶析の科学, JPN6018028449, 2002, pages 56 - 102, ISSN: 0004583468 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11123338B2 (en) | C-met modulator pharmaceutical compositions | |
US11254649B2 (en) | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone | |
KR102354963B1 (ko) | N-{4-[(6,7-다이메톡시퀴놀린-4-일)옥시]페닐}-n'-(4-플루오로페닐) 사이클로프로판-1,1-다이카복스아마이드의 결정질 고체 형태, 제조 방법 및 사용 방법 | |
JP2017505796A5 (ja) | ||
BR112017028516B1 (pt) | Sal de fumarato cristalino, seu uso, processo de preparação do mesmo e composição farmacêutica | |
TWI833686B (zh) | Lsd1 抑制劑之調配物 | |
US20240156804A1 (en) | C-Met Modulator Pharmaceutical Compositions | |
JP2023531078A (ja) | 化合物の結晶形態 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190626 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200528 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200609 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200907 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201105 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210506 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210506 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20210525 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210624 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210805 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210810 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20210903 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20210907 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220614 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20221206 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20221213 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230309 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230331 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230613 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230824 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7338950 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |